Beta Bionics Faces Securities Fraud Suit Over iLet Safety Failures

The litigation, spearheaded by the firm Hagens Berman, targets the period between July 30, 2025, and February 24, 2026. During this window, Beta Bionics executives frequently touted the iLet device as a low-engagement, highly automated solution. When initial FDA scrutiny emerged in late 2025, CEO Sean Saint characterized the agency’s Form 483 observations as routine procedural matters involving complaint definitions rather than core product safety.

However, a January 2026 warning letter from the FDA contradicted these assurances. The agency cited systemic failures, including the company’s inability to analyze quality data and a failure to report device malfunctions linked to serious health outcomes within the mandatory 30-day window. Investors who suffered losses during the class period have until November 3, 2026, to file as lead plaintiffs. Hagens Berman partner Reed Kathrein noted the investigation is focused on whether the company prioritized revenue streams over patient safety protocols.